Literature DB >> 20655893

Correlation of a multi-cytokine panel with clinical disease activity in patients with rheumatoid arthritis.

Nataliya Milman1, Jacob Karsh, Ronald A Booth.   

Abstract

OBJECTIVE: Explore the potential use of a cytokine panel as biochemical markers of disease activity in rheumatoid arthritis (RA) patients. DESIGN AND METHODS: 57 adult RA patients were assessed using five validated clinical disease activity tools: Health Assessment Questionnaire (HAQ), standard 28-joint Disease Activity Score (DAS28), DAS28 using C-reactive protein (DAS28-CRP), Clinical Disease Activity Index (CDAI), and Simple Disease Activity Index (SDAI). Plasma cytokine levels (IL-2, IL-4, IL-6, IL-8, IL-10, VEGF, IFN-γ, TNF-α, IL1α, IL1β, MCP1, and EGF) were measured in 47 of the 57 patients and correlated with clinical indicators.
RESULTS: We found significant correlations between plasma levels of IL-6 and all clinical measures of disease activity; Spearman coefficients (p values) were: HAQ: 0.347(0.017); DAS28: 0.409(0.005); DAS-CRP: 0.378(0.011); CDAI: 0.312(0.033); SDAI: 0.310(0.039); ESR: 0.448(0.002); and CRP: 0.513(0.001). IFN-γ also correlated with DAS-CRP: 0.309(0.039) and SDAI: 0.301(0.044). Furthermore, the levels of IL-6 and IFN-γ increased significantly with worsening disease, as defined by the European League Against Rheumatism (EULAR) classification of disease activity.
CONCLUSION: A significant correlation between plasma levels of IL-6 and clinical disease activity in patients with RA suggests a future role of IL6 as a disease activity marker.
Copyright © 2010. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20655893     DOI: 10.1016/j.clinbiochem.2010.07.012

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  23 in total

1.  Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis.

Authors:  Roma Pahwa; Uma Kumar; Nibhriti Das
Journal:  Mol Cell Biochem       Date:  2016-02-23       Impact factor: 3.396

2.  Outcome prediction using clinical scores and biomarkers in patients with presumed severe infection in the emergency department.

Authors:  J Wilhelm; S Hettwer; D Hammer; M Schürmann; A Christoph; M Amoury; T Klöss; R Finke; H Ebelt; K Werdan
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-08-10       Impact factor: 0.840

3.  Tofacitinib restores the inhibition of reverse cholesterol transport induced by inflammation: understanding the lipid paradox associated with rheumatoid arthritis.

Authors:  S Pérez-Baos; J I Barrasa; P Gratal; A Larrañaga-Vera; I Prieto-Potin; G Herrero-Beaumont; R Largo
Journal:  Br J Pharmacol       Date:  2017-08-03       Impact factor: 8.739

4.  HOTAIR and THRIL Long Non Coding RNAs and Their Target Genes in Rheumatoid Arthritis patients.

Authors:  Engy Medhat; Ghada Ayeldeen; Hanan Hosni Ahmed; Olfat Shaker; Tamer Gheita; Sara Salama Ashour
Journal:  Rep Biochem Mol Biol       Date:  2022-01

5.  Patterns of circulatory and peripheral blood mononuclear cytokines in rheumatoid arthritis.

Authors:  Fawaz Y Azizieh; Khaled Al Jarallah; Diaa Shehab; Renu Gupta; Kamaludin Dingle; Raj Raghupathy
Journal:  Rheumatol Int       Date:  2017-07-19       Impact factor: 2.631

6.  Logistic regression analysis of damp-heat and cold-damp impeding syndrome of rheumatoid arthritis: a perspective in Chinese medicine.

Authors:  Zhi-Zhong Wang; Yong-Fei Fang; Yong Wang; Fang-Xiang Mu; Jun Chen; Qing-Hua Zou; Bing Zhong; Jing-Yi Li; Gan-Ping Bo; Rong-Hua Zhang
Journal:  Chin J Integr Med       Date:  2012-08-02       Impact factor: 1.978

7.  Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity.

Authors:  Jeffrey R Curtis; Annette H van der Helm-van Mil; Rachel Knevel; Tom W Huizinga; Douglas J Haney; Yijing Shen; Saroja Ramanujan; Guy Cavet; Michael Centola; Lyndal K Hesterberg; David Chernoff; Kerri Ford; Nancy A Shadick; Max Hamburger; Roy Fleischmann; Edward Keystone; Michael E Weinblatt
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-12       Impact factor: 4.794

8.  Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.

Authors:  Sudha Visvanathan; Mahboob U Rahman; Edward Keystone; Mark Genovese; Lars Klareskog; Elizabeth Hsia; Michael Mack; Jacqui Buchanan; Michael Elashoff; Carrie Wagner
Journal:  Arthritis Res Ther       Date:  2010-11-17       Impact factor: 5.156

9.  Fatigue assessment by FACIT-F scale in Pakistani cohort with Rheumatoid Arthritis (FAF-RA) study.

Authors:  Abrar Ahmed Wagan; Abdul Raheem; Afra Bhatti; Taimoor Zafar
Journal:  Pak J Med Sci       Date:  2021 Jul-Aug       Impact factor: 1.088

10.  Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy alone.

Authors:  Carl K Edwards; Julie S Green; Hans-Dieter Volk; Michael Schiff; Brian L Kotzin; Hiroaki Mitsuya; Tatsuya Kawaguchi; Ken-Mei Sakata; John Cheronis; David Trollinger; Danute Bankaitis-Davis; Charles A Dinarello; David A Norris; Michael P Bevilacqua; Mayumi Fujita; Gerd-Rudiger Burmester
Journal:  Front Immunol       Date:  2012-12-04       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.